Figure 1.
Changes in ACQ, AQLQ, daily dose of OCS and number of severe exacerbations per year during the discontinuation of omalizumab – data for 9 patients
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.